Wealth Effects LLC Has $189,000 Stock Position in ImmunityBio, Inc. (NASDAQ:IBRX)

Wealth Effects LLC cut its holdings in shares of ImmunityBio, Inc. (NASDAQ:IBRX) by 18.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 73,700 shares of the company’s stock after selling 16,800 shares during the period. Wealth Effects LLC’s holdings in ImmunityBio were worth $189,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the business. Captrust Financial Advisors acquired a new stake in ImmunityBio in the third quarter valued at about $41,000. Algert Global LLC bought a new position in shares of ImmunityBio in the second quarter worth about $86,000. Virtu Financial LLC acquired a new stake in shares of ImmunityBio in the 3rd quarter valued at approximately $51,000. Mutual Advisors LLC bought a new stake in shares of ImmunityBio during the 4th quarter valued at approximately $41,000. Finally, Dimensional Fund Advisors LP acquired a new position in ImmunityBio during the 2nd quarter worth approximately $105,000. Institutional investors and hedge funds own 8.58% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on IBRX. EF Hutton Acquisition Co. I raised shares of ImmunityBio to a “strong-buy” rating in a research note on Wednesday, October 23rd. D. Boral Capital restated a “buy” rating and set a $30.00 price objective on shares of ImmunityBio in a research report on Monday. Finally, BTIG Research started coverage on ImmunityBio in a research report on Friday, January 10th. They issued a “buy” rating and a $6.00 target price for the company.

ImmunityBio Stock Down 1.6 %

IBRX stock opened at $3.08 on Wednesday. The company has a fifty day moving average price of $3.43 and a 200-day moving average price of $4.03. ImmunityBio, Inc. has a 52-week low of $2.28 and a 52-week high of $10.53.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.